As LMP1 is an attractive and promising target for EBV-positive NPC, our group successfully developed a DNAzyme (DZ1) that was engineered to specifically target the LMP1 mRNA.255 DZ1 treatment can reverse malignant phenotypes caused by LMP1 and increase the radiosensitivity of NPC, indicating the potential for DZ1 therapeutic approaches for the treatment of EBV-related cancers.99,255,354,355. Here, PDLIM7 is linked to cancer.